US Classes424/133.1, Structurally-modified antibody, immunoglobulin, or fragment thereof (e.g., chimeric, humanized, CDR-grafted, mutated, etc.)530/387.3, Chimeric, mutated, or recombined hybrid (e.g., bifunctional, bispecific, rodent-human chimeric, single chain, rFv, immunoglobulin fusion protein, etc.)530/389.1, Polyclonal antibody or immunogloblin of identified binding specificity536/23.53Immunoglobulin
Attorney, Agent or Firm
International ClassesA61K 39/395
Compositions comprising antigen binding polypeptides that bind specifically to Receptor For Advanced Glycation End-product (RAGE) and comprises: one or more complementarity determining regions (CDRs) with improved binding efficiency over a parental monoclonal antibody to RAGE are described. Antibodies containing the CDR's and methods of treating a RAGE-related disease or disorder comprising administering to the subject a therapeutically effective amount of the compositions of the invention are also provided.